Andre H Goy
Overview
Explore the profile of Andre H Goy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1017
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ip A, Kabat M, Fogel L, Alkhatatneh H, Voss J, Gupta A, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002289
Advancements in mantle cell lymphoma (MCL) have illuminated the disease's molecular diversity, leading to a wide variation in the outcomes observed in MCL. Current prognostic risk scores are continuously revised...
2.
Danish A, Della Pia A, Fogel L, Alkhatatneh H, Zhao C, Varughese T, et al.
Front Oncol
. 2024 Sep;
14:1425506.
PMID: 39228984
Background And Purpose: The aim of this study was to determine the prevalence of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after...
3.
Ip A, Della Pia A, Goy A
Clin Lymphoma Myeloma Leuk
. 2024 Mar;
24(8):491-505.
PMID: 38493059
Progress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to...
4.
Oluwole O, Forcade E, Munoz J, de Guibert S, Vose J, Bartlett N, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):366-372.
PMID: 38177222
ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs)...
5.
Vose J, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, et al.
J Hematol Oncol
. 2023 Dec;
16(1):122.
PMID: 38104096
Background: Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs...
6.
Ip A, Petrillo A, Della Pia A, Lee G, Gill S, Varughese T, et al.
Leuk Lymphoma
. 2023 Sep;
64(14):2225-2235.
PMID: 37740588
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination...
7.
Neelapu S, Jacobson C, Ghobadi A, Miklos D, Lekakis L, Oluwole O, et al.
Blood
. 2023 Feb;
141(19):2307-2315.
PMID: 36821768
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with...
8.
Della Pia A, Kim G, Ip A, Ahn J, Liu Y, Kats S, et al.
PLoS One
. 2022 Dec;
17(12):e0266584.
PMID: 36454941
Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma...
9.
Della Pia A, Zhao C, Jandir P, Gupta A, Batistick M, Kim G, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077782
Lymphoma patients are at greater risk of severe consequences from COVID-19 infection, yet most reports of COVID-19-associated outcomes were published before the advent of COVID-19 vaccinations and monoclonal antibodies (mAbs)....
10.
Ip A, Della Pia A, Kim G, Lofters J, Behrmann J, Patel D, et al.
Front Oncol
. 2022 Jul;
12:923809.
PMID: 35774119
Introduction: Cytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations...